F ate Therapeutics (NASDAQ:FATE) stock closed 12% higher Monday after soaring as much as 73% on news that the first patient in the company's Phase 1 Autoimmunity study for its CAR T-cell therapy ...

Find the latest Fate Therapeutics, Inc. FATE analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.